Three Prostate Cancer Numbers, One Overwhelmed Family

For this composite account, call him Leon. He was 70 when a biopsy found prostate cancer. A few days later, he sat at his sister’s kitchen table with two siblings, a portal open on a tablet, and a notebook between them.

His sister had copied down three entries: PSA 8.7 ng/mL, Grade Group 2, and cT2a. The pathology report also contained the line that had stopped them: “Gleason score 3+4=7.”

They treated the entries as though they were competing answers to one question. One sibling thought the 8.7 was the cancer’s stage. Another assumed Grade Group 2 meant stage 2.

Leon circled the 7 and asked why a score that sounded high was paired with a group that sounded lower.

Their confusion was reasonable. These results can appear close together in a medical record, and clinicians may use them in the same discussion. Yet each describes a different feature of the cancer. They overlap only later, when a specialist considers the whole record.

Leon’s sister drew lines across the notebook page. The first section was for PSA. The next was for the biopsy. The last was for where the cancer had been found.

PSA is a blood measurement

PSA stands for prostate-specific antigen, a protein made by prostate cells. A PSA test measures how much of that protein is in the blood, usually in nanograms per milliliter, written as ng/mL. A nanogram is one-billionth of a gram.

Leon’s result was 8.7 ng/mL. That number was the concentration of PSA in his blood sample. It was not the size of a tumor, the percentage of his prostate affected, or a count of cancer cells.

Cancer can raise PSA, but it is not the only cause. A noncancerous enlarged prostate can raise it. Inflammation or infection may raise it, and some recent procedures can affect the result. Certain medicines can lower PSA, which may change how a clinician interprets the number.

This is why PSA is better understood as a signal that needs context than as a label attached to the cancer. After a diagnosis, the specialist may look at the level, earlier results, prostate size, medicines, and other parts of the record rather than reading the decimal in isolation.

A PSA result can help with risk assessment and later monitoring. It cannot show under a microscope how abnormal the cancer cells look, and it cannot map where the cancer is in the body.

In the notebook, Leon’s sister wrote “blood” beside 8.7. That one word settled the first mix-up.

Gleason and Grade Group describe appearance

The biopsy supplied a different kind of information. A pathologist, a doctor who examines tissue and cells, had studied small samples taken from Leon’s prostate.

Prostate cancer cells often form patterns. The Gleason system assigns numbers to those patterns according to how much the tissue’s structure differs from usual prostate tissue. In modern practice, the patterns generally reported in diagnosed cancer are pattern 3, pattern 4, and pattern 5, with higher patterns looking less like normal prostate glands.

The pathologist identified the main pattern in Leon’s sampled cancer as pattern 3 and the next most prominent pattern as pattern 4. That produced the Gleason score 3+4=7.

The order matters. A score of 3+4 and a score of 4+3 both total 7, but they do not describe the same balance of patterns. In 3+4, pattern 3 is more common in the sampled tissue. In 4+3, the more abnormal pattern 4 is more common.

Grade Group translates Gleason findings into a scale from 1 through 5. Grade Group 1 corresponds to Gleason 3+3=6. Grade Group 2 generally corresponds to Gleason 3+4=7, while Grade Group 3 generally corresponds to 4+3=7. Grade Groups 4 and 5 cover higher-pattern combinations.

That is how Leon could have a Gleason score of 7 and a Grade Group of 2 without either entry being a mistake. They were two ways of reporting related pathology information, rather than two separate measurements competing with each other.

Grade describes appearance and expected behavior based on the tissue examined. It does not directly say where the cancer is. A biopsy also samples parts of the prostate rather than removing and examining the entire organ, so a later pathology assessment can sometimes differ if more tissue becomes available.

His sister turned back to the notebook and wrote “cells under microscope” beside Grade Group 2. She left the circled 7 in place, but connected it to the group with a line.

Stage describes extent

Stage addresses another question: how far has the cancer been found to extend?

Prostate cancer staging often uses the TNM system. T describes the primary tumor in or around the prostate. N records whether nearby lymph nodes are involved. M records whether distant spread, called metastasis, has been found.

Leon’s note included cT2a. The lowercase c meant clinical stage, an estimate based on information available before any operation to remove the prostate. T2a indicated that the clinician believed the tumor was confined to the prostate and involved no more than half of one side.

That notation did not mean “stage 2a” in ordinary speech. T2a was one component of staging, and his siblings had turned it into a complete stage because the letters and numbers looked finished on the portal.

Clinical stage may draw on the physical examination, imaging, biopsy findings, and other available records. If the prostate is later removed, examination of that tissue can produce a pathological stage, marked with a lowercase p. The clinical and pathological stages may differ because the second assessment has more tissue to examine.

Clinicians can also combine TNM findings with PSA and Grade Group to assign an overall prognostic stage group, usually expressed with Roman numerals from I through IV. This is one reason the terms feel tangled: PSA, grade, and anatomical extent describe different features, but the overall stage grouping may incorporate all of them.

A stage entry can change as new information arrives. That does not always mean the cancer suddenly changed between appointments. Sometimes the record changed because imaging, lymph-node assessment, or surgical pathology revealed something that had not been visible earlier.

On the notebook page, Leon’s sister wrote “where found” beside cT2a. She did not add an overall Roman-numeral stage because that was not clearly documented in the records they had.

Why none of these numbers chooses treatment

By the end of the family meeting, the page looked less tidy than it had at the start. That helped. The crossed-out assumptions showed where one result had been asked to do another result’s job.

PSA offered information from blood. Grade Group described the sampled tissue’s appearance. Stage described known extent. A clinician could consider them together, but no single entry captured Leon’s health, priorities, likely life expectancy, urinary function, or the possible burdens of different approaches.

Other details can matter too, including how many biopsy samples contained cancer, how much cancer appeared in them, imaging findings, genomic test results when such testing is used, and whether serious health conditions could affect the choices under discussion. The relevance of each detail varies from person to person.

This explainer cannot identify Leon’s best treatment, predict whether his cancer will grow, or interpret another person’s results from matching numbers. Two people can share a PSA or Grade Group while having meaningful differences elsewhere in their records.

A urologist or another prostate cancer specialist can explain how the complete findings fit together. A pathologist can clarify wording in the biopsy report, usually through the treating clinician, while a radiation oncologist or medical oncologist may interpret the same record from a different treatment perspective. The useful question for the care team is which result describes blood, which describes tissue, and which describes extent in that person’s case.

Leon took the notebook home. Eight months later, it still held the original page, including the circle around the 7 and the line connecting it to Grade Group 2.

Questions people ask

Is Grade Group 2 the same as stage 2?

No. Grade Group 2 describes how the sampled cancer tissue looked under a microscope and generally corresponds to Gleason 3+4=7. Stage describes where cancer has been found, and an overall stage group may also incorporate PSA and other findings. The treating specialist can identify which staging system appears in the record.

Can a

PSA result show whether prostate cancer has spread?

PSA alone cannot locate cancer or confirm spread. It is a blood measurement that may contribute to risk assessment, while examinations, imaging, and sometimes tissue from lymph nodes or surgery provide information about extent. The meaning of a particular PSA depends on the rest of the person’s history and results.

Why might the stage change later?

An early clinical stage uses the information available at diagnosis. Later imaging or examination of tissue removed during surgery may reveal details that were not previously visible, producing a different stage entry. A change in documentation can reflect added information rather than a sudden change in the cancer itself.

Which number tells a family what treatment should happen?

None does that alone. Treatment conversations may draw on PSA, Grade Group, stage, biopsy details, other health conditions, and the person’s priorities, with different specialists explaining the tradeoffs. At the kitchen table, Leon’s family kept those discussions separate by writing one plain phrase beside each result in the notebook.